To include your compound in the COVID-19 Resource Center, submit it here.

GlycoMimetics reports updated Phase I/II AML data for GMI-1271

GlycoMimetics (NASDAQ:GLYC) reported updated data at the American Society of Hematology meeting from a Phase I/II trial of GMI-1271 to treat acute myelogenous leukemia (AML). The company plans to start a Phase III

Read the full 331 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE